Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study

Table 1 Patient disposition

	Number (%) of patients
	Placebo	Fulranumab 9 mg
Randomized	17 (100)	14 (100)
Received all 3 doses of study drug	15 (88)	10 (71)
Completed the study	14 (82)	10 (71)
Withdrew from the study	3 (18)	4 (29)
Sponsor discontinued the study	1 (6)	0 (0)
Patient withdrew consent	2 (12)	0 (0)
Other	0 (0)	4^a (29)

^aTwo patients did not meet inclusion/exclusion criteria, 1 patient missed the Week 9 dose, and 1 patient withdrew due to the clinical hold

ISSN: 1471-2490